Related Experiment Video
Updated: Apr 5, 2026
CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis
Published on: April 25, 2022
MMP1, 2, 3, 7, and 9 gene polymorphisms and urinary cancer risk: a meta-analysis
11 Department of Urology, The First Hospital of China Medical University , Shenyang, People's Republic of China .
Background:
The matrix metalloproteinases (MMPs) are a family of highly conserved, metal-dependent proteolytic enzymes that play an important role in tumor invasion and metastasis. Many studies have been carried out on the association between polymorphisms in the MMP1, MMP2, MMP3, MMP7, and MMP9 genes and urinary cancer risk. However, the data from these published studies are conflicting and have low statistical power.
Methods:
In this study, we performed a meta-analysis of 12 different publications from the PubMed and WanFang databases, published up to May 2015, to better assess the purported associations. Odds ratios (OR) and 95% confidence intervals (CI) were determined to reveal association strengths.
Results:
Some significant associations were found. For the MMP1 -1607 1G/2G polymorphism, a negative association was identified for the 2G allele in bladder cancer (2G2G+2G1G vs. 1G1G: OR = 0.57, 95% CI = 0.36-0.93, pheterogeneity = 0.001) and renal cell carcinoma (2G1G vs. 1G1G: OR = 0.57, 95% CI = 0.39-0.82, pheterogeneity = 0.567). For the MMP2 -1306 C/T polymorphism, there was a negative association with the T allele for bladder cancer in the Asian population (TT+TC vs. CC: OR = 0.41, 95% CI = 0.18-0.94, pheterogeneity = 0.195). For the MMP7 -181 A/G polymorphism, a decreased bladder cancer risk was found (G-allele vs. A-allele: OR = 0.81, 95% CI = 0.66-0.98, pheterogeneity =0.325).
Conclusion:
In summary, our study showed evidence that genetic polymorphisms in MMP1 for all populations, but only in the Asian population for MMP2 and MMP7, may protect against bladder cancer risk. Future studies with larger sample sizes are warranted to further evaluate these associations in more detail.
Insights
Genetic polymorphisms in MMP1, MMP2, and MMP7 may protect against urinary cancers. Specifically, MMP1 gene variants show a protective effect across all populations, while MMP2 and MMP7 offer protection in Asian populations for bladder cancer.
Area of Science:
- Genetics
- Oncology
- Molecular Biology
Background:
- Matrix metalloproteinases (MMPs) are crucial in tumor invasion and metastasis.
- Previous studies on MMP gene polymorphisms and urinary cancer risk yielded conflicting results with limited statistical power.
Purpose of the Study:
- To conduct a meta-analysis to clarify the association between MMP gene polymorphisms and urinary cancer risk.
- To assess the role of MMP1, MMP2, MMP3, MMP7, and MMP9 gene polymorphisms in urinary cancer development.
Main Methods:
- A meta-analysis of 12 studies from PubMed and WanFang databases (up to May 2015).
- Calculation of odds ratios (OR) and 95% confidence intervals (CI) to determine association strengths.
Main Results:
- MMP1 -1607 1G/2G polymorphism showed a protective association for the 2G allele in bladder cancer and renal cell carcinoma.
- MMP2 -1306 C/T polymorphism was negatively associated with the T allele in Asian bladder cancer patients.
- MMP7 -181 A/G polymorphism demonstrated a decreased risk for bladder cancer (G-allele).
Conclusions:
- Genetic polymorphisms in MMP1 may protect against urinary cancer in all populations.
- MMP2 and MMP7 polymorphisms appear protective against bladder cancer specifically in the Asian population.
- Larger studies are recommended to further validate these genetic associations.
